Sara Alavi

687 total citations
22 papers, 438 citations indexed

About

Sara Alavi is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sara Alavi has authored 22 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Sara Alavi's work include Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (6 papers) and CAR-T cell therapy research (4 papers). Sara Alavi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (6 papers) and CAR-T cell therapy research (4 papers). Sara Alavi collaborates with scholars based in Germany, Australia and Iran. Sara Alavi's co-authors include Helen Rizos, Ashleigh Stewart, Elena Shklovskaya, Su Yin Lim, Richard Kefford, Jalid Sehouli, Robyn P.M. Saw, Jean Yang, Matteo S. Carlino and Alexander M. Menzies and has published in prestigious journals such as Nature Communications, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

Sara Alavi

20 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara Alavi Germany 11 234 173 114 63 46 22 438
Yuefei Yu United States 14 120 0.5× 236 1.4× 266 2.3× 29 0.5× 45 1.0× 29 476
Mehdi Montazer Iran 13 131 0.6× 63 0.4× 163 1.4× 24 0.4× 46 1.0× 35 365
K. Oliva Australia 8 164 0.7× 67 0.4× 120 1.1× 27 0.4× 50 1.1× 13 431
Peirong Yang United States 7 188 0.8× 63 0.4× 217 1.9× 16 0.3× 37 0.8× 11 403
Martin J. Bury United States 10 202 0.9× 44 0.3× 55 0.5× 85 1.3× 65 1.4× 23 314
Elizabeth K. Lee United States 13 309 1.3× 120 0.7× 205 1.8× 63 1.0× 153 3.3× 34 662
Sarah Nersesian Canada 11 313 1.3× 271 1.6× 143 1.3× 21 0.3× 133 2.9× 27 592
Yung Jue Bang South Korea 10 124 0.5× 55 0.3× 149 1.3× 42 0.7× 86 1.9× 30 412
Sharon Pattison New Zealand 12 161 0.7× 67 0.4× 147 1.3× 25 0.4× 102 2.2× 31 482
J. Wolf Germany 10 167 0.7× 53 0.3× 248 2.2× 60 1.0× 214 4.7× 29 530

Countries citing papers authored by Sara Alavi

Since Specialization
Citations

This map shows the geographic impact of Sara Alavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Alavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Alavi more than expected).

Fields of papers citing papers by Sara Alavi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Alavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Alavi. The network helps show where Sara Alavi may publish in the future.

Co-authorship network of co-authors of Sara Alavi

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Alavi. A scholar is included among the top collaborators of Sara Alavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Alavi. Sara Alavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tseng, Hsin‐Yi, Sara Alavi, Stuart Gallagher, et al.. (2024). BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti‐CTLA‐4 treatment. Pigment Cell & Melanoma Research. 37(6). 744–751. 2 indexed citations
2.
Hersey, Peter, Hsin‐Yi Tseng, Sara Alavi, & Jessamy Tiffen. (2024). X and Y Differences in Melanoma Survival Between the Sexes. Pigment Cell & Melanoma Research. 38(1). e13194–e13194.
3.
4.
Ahmed, Farzana, Hsin‐Yi Tseng, Antonio Ahn, et al.. (2021). Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. Journal of Investigative Dermatology. 142(5). 1444–1455.e10. 16 indexed citations
5.
Lim, Su Yin, Sara Alavi, Elena Shklovskaya, et al.. (2021). Melanoma Cell State-Specific Responses to TNFα. Biomedicines. 9(6). 605–605. 3 indexed citations
6.
Lee, Jenny, Elena Shklovskaya, Su Yin Lim, et al.. (2020). Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications. 11(1). 1897–1897. 193 indexed citations
7.
Armbrust, Robert, Sara Alavi, Frank Chen, et al.. (2020). Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. International Journal of Gynecological Cancer. 30(10). 1603–1607. 4 indexed citations
8.
Taube, Eliane T., Lisa Antonia Dröge, Radoslav Chekerov, et al.. (2020). Angiosarcomas of Primary Gynecologic Origin – A Case Series and Review of the Literature. Anticancer Research. 40(10). 5743–5750. 6 indexed citations
9.
Alavi, Sara, Rolf Richter, Maren Keller, et al.. (2020). Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). International Journal of Gynecological Cancer. 30(4). 509–514. 10 indexed citations
10.
11.
Woopen, Hannah, Rolf Richter, Radoslav Chekerov, et al.. (2019). Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Supportive Care in Cancer. 28(1). 73–78. 17 indexed citations
12.
13.
Alavi, Sara, Ashleigh Stewart, Richard Kefford, et al.. (2018). Interferon Signaling Is Frequently Downregulated in Melanoma. Frontiers in Immunology. 9. 1414–1414. 28 indexed citations
14.
Pietzner, Klaus, Sara Nasser, Sara Alavi, et al.. (2018). Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. Journal of Gynecologic Oncology. 29(6). e93–e93. 28 indexed citations
15.
16.
Alavi, Sara, Matthias Schulz, Andreas Schaumann, Karin Schwarz, & Ulrich W. Thomale. (2017). Valve exchange towards an adjustable differential pressure valve with gravitational unit, clinical outcome of a single-center study. Child s Nervous System. 33(5). 759–765. 10 indexed citations
17.
Alavi, Sara, et al.. (2017). Pleomorphic Rhabdomyosarcoma of the Uterus – Case Report and a Systematic Review of the Literature. Anticancer Research. 37(5). 2509–2514. 6 indexed citations
18.
Shahbazi, Shirin, et al.. (2012). BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Medical Oncology. 30(1). 393–393. 59 indexed citations
19.
Shahbazi, Shirin, Sara Alavi, & Reza Mahdian. (2012). Classification of exon 18 linked variants of VWF gene in von Willebrand disease.. PubMed. 3(1). 77–83. 4 indexed citations
20.
Lieber, Arthur & Sara Alavi. (1970). Rectal stone. Digestive Diseases and Sciences. 15(3). 287–290. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuefei Yu Breakdown of academic impact, for papers by Mehdi Montazer Breakdown of academic impact, for papers by K. Oliva Breakdown of academic impact, for papers by Peirong Yang Breakdown of academic impact, for papers by Martin J. Bury Breakdown of academic impact, for papers by Elizabeth K. Lee Breakdown of academic impact, for papers by Sarah Nersesian Breakdown of academic impact, for papers by Yung Jue Bang Breakdown of academic impact, for papers by Sharon Pattison Breakdown of academic impact, for papers by J. Wolf
Rankless by CCL
2026